Regional Innovation Partnership recoverable advance aid contract No DOS0043899/00Dynacure S.A. • January 20th, 2021 • Pharmaceutical preparations
A French public limited company (société anonyme), with a share capital of EUR 839,907,320.00, registered with the Trade and Companies Register of Creteil under number 320 252 489, and whose registered office is located at:
Regional Innovation Partnership recoverable advance aid contract No DOS0043900/00Special Terms and Conditions • January 20th, 2021 • Dynacure S.A. • Pharmaceutical preparations
A French public limited company (société anonyme), with a share capital of EUR 839,907,320.00, registered with the Trade and Companies Register of Creteil under number 320 252 489, and whose registered office is located at:
LOAN AGREEMENT SEED CAPITAL INVESTMENT EIF N° DOS0137037/00Loan Agreement • January 20th, 2021 • Dynacure S.A. • Pharmaceutical preparations
A French public limited company (société anonyme), with a share capital of EUR 839,907,320, registered with the Trade and Companies Register of Creteil under number 320 252 489, and whose registered office is located at:
DYNACURE SAS CONVERTIBLE BOND TERMS AND CONDITIONSDynacure S.A. • January 20th, 2021 • Pharmaceutical preparations
RESEARCH COLLABORATION AND LICENSE AGREEMENT BETWEEN IONIS PHARMACEUTICALS, INC., AND DYNACURE, SASResearch Collaboration and License Agreement • January 20th, 2021 • Dynacure S.A. • Pharmaceutical preparations • New York
This RESEARCH COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) is made and entered into as of the 19th day of October, 2016 (the “Effective Date”) by and between IONIS PHARMACEUTICALS, INC., a Delaware corporation, having its principal place of business at 2855 Gazelle Court, Carlsbad, CA 92010 (“Ionis”), and Dynacure, SAS (“Dynacure”), a company headquartered in France with its principal place of business at Parc d’innovation, 650 Boulevard Gonthier d’Andernach, 67400 Illkirch Graffenstaden, Strasbourg, France. Dynacure and Ionis each may be referred to herein individually as a “Party” or collectively as the “Parties.”
MWE Execution Copy EXCLUSIVE PATENT SUBLICENSE AGREEMENT (the “Agreement”) BY AND BETWEENExclusive Patent Sublicense Agreement • January 20th, 2021 • Dynacure S.A. • Pharmaceutical preparations
WHEREAS, in the frame of its research activity in the Institut de Génétique et de Biologie Moléculaire et Cellulaire (hereinafter referred to as the “LABORATORY”), the team of Jocelyn LAPORTE has identified and developed a new therapeutic strategy for the treatment of myopathies (“TECHNOLOGY”), and more specifically centronuclear myopathies and Duchenne Muscular Distrophy, objects of patent applications.
